E. Ohman J:or Asset Management AB
Position in NBIX — Neurocrine Biosciences Inc
CIK 2009396
STOCKHOLM, V7
Position in NBIX
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$591,912
+$129,242 QoQ
Shares Held
3,512
0.0% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#448
of 768 holders
Holding Since
Mar 2021
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NBIX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026E. Ohman J:or Asset Management AB holds $7,864,240 across 6 Drug Manufacturers - Specialty & Generic names. NBIX ranks #5 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LNTH |
Lantheus Holdings, Inc.
|
36,937 | $4,097,790 | |
| 2 | ZTS |
Zoetis Inc.
|
15,364 | $1,104,057 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,521 | $824,123 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
19,680 | $666,758 | |
| 5 | NBIX |
Neurocrine Biosciences Inc
This page
|
3,512 | $591,912 | |
| 6 | RDY |
Dr Reddys Laboratories Ltd
|
40,000 | $579,600 |
All Filings in NBIX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $591,912 | 3,512 | Shares | Sole | 2026-07-10 | |
| 2026-03-31 | $462,670 | 3,512 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $498,106 | 3,512 | Shares | Sole | 2026-01-12 | |
| 2022-06-30 | $487,400 | 5,000 | Shares | Sole | 2024-04-05 | |
| 2022-03-31 | $159,375 | 1,700 | Shares | Sole | 2024-04-05 | |
| 2021-09-30 | $374,049 | 3,900 | Shares | Sole | 2024-04-05 | |
| 2021-06-30 | $379,548 | 3,900 | Shares | Sole | 2024-04-05 | |
| 2021-03-31 | $165,325 | 1,700 | Shares | Sole | 2024-04-05 | |
| No filing history on record for this holder in this stock. | ||||||